NBRV News and Press, Nabriva Therapeutics plc From 05/08/20

DUBLIN, Ireland, May 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter fina...

Nano cap Nabriva Therapeutics (NASDAQ: NBRV ) is up  11%  premarket on robust volume on the heels of the publication of post-hoc data from the LEAP 1 and LEAP 2 studies evaluating Xenleta (lefamulin) in adults with moderate-to-severe community-acquired bacterial pneumonia (CA...

DUBLIN, Ireland, May 05, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that Open Forum Infectious Diseases , a...

Inspire Medical Systems (NYSE: INSP ) initiated with Overweight rating and $74 (19% upside) price target at Piper Sandler. More news on: Inspire Medical Systems, Inc., Prevail Therapeutics Inc., Stereotaxis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

DUBLIN, Ireland, April 09, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that the Centers for Medicare and Medica...

DUBLIN, Ireland, April 08, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offe...

3 Penny Stocks To Watch This Week Penny stocks and blue-chips are both experiencing big bouts of volatility this week. This was partially due to the uncertainty surrounding the coronavirus. But we’ve also got to take into consideration the current state of the economy. Not only are ...

Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Buy rating and $200 (93% upside) price target at Berenberg. More news on: Summit Therapeutics plc, SpringWorks Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Arrowhead Pharmaceuticals (NASDAQ: ARWR ) initiated with Neutral rating and $45 (107% upside) price target at Goldman Sachs. More news on: Arrowhead Pharmaceuticals, Inc., Ocular Therapeutix, Inc., Blueprint Medicines Corporation, Healthcare stocks news, Stocks on the move, , Read more...

The following slide deck was published by Nabriva Therapeutics plc in conjunction with their 2019 Q4 earnings Read more ...